US › Healthcare

Prelude Therapeutics Inc (PRLD)

US · Healthcare · Biotechnology

$4.52+2.96%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$4.6M

Net profit

$-10.4M

Profit YoY

+67.6%

EPS

$-0.13

EPS estimate

$-0.27

Net margin

-226.7%

EPS came in at -0.13 against a street estimate of -0.27 — a beat of 51.9%.

Key statistics

Market cap

$366.4M

Forward P/E

0.0

P/B

6.09

Book value

$0.73

EPS (TTM)

$-1.00

52-week high

$5.69

52-week low

$0.75

50-day MA

$4.33

200-day MA

$3.12

Beta

0.95

Analyst view

Analysts rate Prelude Therapeutics Inc a buy (3 buy, 0 hold, 1 sell out of 4) with an average price target of $8.00.

Shareholding

Insiders

13.80%

Institutions

64.86%

Largest institutional holders

Fund	Stake
Orbimed Advisors, LLC	13.70%
Baker Bros Advisors LP	12.71%
Kynam Capital Management, LP	2.00%
Vanguard Capital Management, LLC	1.54%
EcoR1 Capital, LLC	1.19%
Two Sigma Investments LLC	1.16%
Sphera Funds Management Ltd.	0.70%
Acadian Asset Management LLC	0.64%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Prelude Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.